BMRN

#861
BioMarin Pharmaceuticals Inc
55.22 USD
+0.62%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
54.72
55.22
Range Annuel
50.76
66.28
Changement quotidien
+0.62%
Changement Mensuel
-2.56%
Evolution sur 6 mois
+5.50%
Changement Annuel
-7.38%
Clôture Précédente
54.88
Open
54.75
Bid
Ask
Low
54.72
High
55.22
Volume
54
Open full chart

Financials

Overview Relevé Statistics
Quarterly Annual
  • Market Capitalization 10.62 B
  • Employee 3 221
  • Founded N/A
  • CEO Alexander Hardy
  • Website www.biomarin.com
  • Headquarter Delaware, United States
  • FIGI BBG000CZWZ05
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
33.02
Price to sales ratio
3.64

BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.

Nouvelles